FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385348531> ?p ?o ?g. }

• W4385348531 endingPage "239" @default.
• W4385348531 startingPage "230" @default.
• W4385348531 abstract "Aim . Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective of this study was to explore the relationship between plasma BCAAs and different stages of cardiovascular disorders. Material and methods . In our cross-sectional study, plasma BCAAs (valine, leucine and isoleucine) in individuals without cardiovascular diseases (CVDs) (nonCVD group, total n=27, with n=16 healthy, but with metabolic disorders) were compared to patients diagnosed with CVDs [CVD group, total n=109, being n=61 hypertension (n=31 with signs of beginning of myocardial remodeling) and n=48 patients with coronary artery disease (CAD)]. Results. The plasma concentration of BCAAs was significantly higher in the group of patients with cardiovascular disease compared with the healthy group (p<0.05 for all amino acids tested): valine concentration was 238.7 [219.6; 267.0] μM in the non-CVD group and 261.2 [233.8; 298.7] μM in the CVD group; leucine concentration was 134.8 [122.4; 153.2] μM and 146.8 [129.0; 166.6] μM, respectively; and isoleucine 72.7 [65.3; 84.4] μM and 81.7 [68.0; 96.2] μM, respectively. Leucine and isoleucine concentration levels were minimal in the healthy participant subgroup and maximal in the IBS patient subgroup. No statistically significant differences in BCAAs concentrations were found in the subgroups without CAD. Significant increases in concentrations were observed in the subgroups of patients with CAD as follows: valine concentration was 256.3 [219.0; 297.9] μM in hypertension group and 261.7 [236.5; 307.5] μM in CAD group; leucine concentration was 141.8 [123.5; 166.6] μM and 154.1 [134.7; 172.7] μM, respectively, and isoleucine 72.8 [65.7; 94.0] μM and 85.7 [74.9; 101.7] μM, respectively. BCAAs profiles in all participants with metabolic disorders had “good” diagnostic accuracy with area under the receiver operating characteristics curve being 0.72, 0.70 and 0.70 for valine, leucine and isoleucine, respectively. Conclusion . BCAAs concentrations are elevated with higher severity of the cardiovascular disorder and exhibit potential as early independent indicators of coronary artery disease." @default.
• W4385348531 created "2023-07-29" @default.
• W4385348531 creator A5000298447 @default.
• W4385348531 creator A5002907636 @default.
• W4385348531 creator A5009263302 @default.
• W4385348531 creator A5010729161 @default.
• W4385348531 creator A5017624762 @default.
• W4385348531 creator A5019792472 @default.
• W4385348531 creator A5023858863 @default.
• W4385348531 creator A5025249324 @default.
• W4385348531 creator A5027496241 @default.
• W4385348531 creator A5058618465 @default.
• W4385348531 creator A5071390552 @default.
• W4385348531 creator A5089938168 @default.
• W4385348531 creator A5092452616 @default.
• W4385348531 date "2023-07-27" @default.
• W4385348531 modified "2023-09-27" @default.
• W4385348531 title "Plasma branched-chain amino acid concentrations in individuals without cardiovascular diseases versus patients diagnosed with hypertension and coronary artery disease" @default.
• W4385348531 cites W1987100478 @default.
• W4385348531 cites W2001651594 @default.
• W4385348531 cites W2017771330 @default.
• W4385348531 cites W2041256183 @default.
• W4385348531 cites W2048862063 @default.
• W4385348531 cites W2056467018 @default.
• W4385348531 cites W2079014566 @default.
• W4385348531 cites W2079195246 @default.
• W4385348531 cites W2091990362 @default.
• W4385348531 cites W2099783126 @default.
• W4385348531 cites W2122367003 @default.
• W4385348531 cites W2309231815 @default.
• W4385348531 cites W2309791126 @default.
• W4385348531 cites W2337133379 @default.
• W4385348531 cites W2492591406 @default.
• W4385348531 cites W2587537033 @default.
• W4385348531 cites W2772091244 @default.
• W4385348531 cites W2790486637 @default.
• W4385348531 cites W2884761694 @default.
• W4385348531 cites W2973342066 @default.
• W4385348531 cites W3014301292 @default.
• W4385348531 cites W3023135331 @default.
• W4385348531 cites W3033026113 @default.
• W4385348531 cites W3111318414 @default.
• W4385348531 cites W3112555401 @default.
• W4385348531 cites W3128136927 @default.
• W4385348531 cites W3185089356 @default.
• W4385348531 cites W4307240323 @default.
• W4385348531 doi "https://doi.org/10.20996/1819-6446-2023-2894" @default.
• W4385348531 hasPublicationYear "2023" @default.
• W4385348531 type Work @default.
• W4385348531 citedByCount "0" @default.
• W4385348531 crossrefType "journal-article" @default.
• W4385348531 hasAuthorship W4385348531A5000298447 @default.
• W4385348531 hasAuthorship W4385348531A5002907636 @default.
• W4385348531 hasAuthorship W4385348531A5009263302 @default.
• W4385348531 hasAuthorship W4385348531A5010729161 @default.
• W4385348531 hasAuthorship W4385348531A5017624762 @default.
• W4385348531 hasAuthorship W4385348531A5019792472 @default.
• W4385348531 hasAuthorship W4385348531A5023858863 @default.
• W4385348531 hasAuthorship W4385348531A5025249324 @default.
• W4385348531 hasAuthorship W4385348531A5027496241 @default.
• W4385348531 hasAuthorship W4385348531A5058618465 @default.
• W4385348531 hasAuthorship W4385348531A5071390552 @default.
• W4385348531 hasAuthorship W4385348531A5089938168 @default.
• W4385348531 hasAuthorship W4385348531A5092452616 @default.
• W4385348531 hasBestOaLocation W43853485311 @default.
• W4385348531 hasConcept C126322002 @default.
• W4385348531 hasConcept C134018914 @default.
• W4385348531 hasConcept C185592680 @default.
• W4385348531 hasConcept C2776580952 @default.
• W4385348531 hasConcept C2777305461 @default.
• W4385348531 hasConcept C2777573094 @default.
• W4385348531 hasConcept C2778213512 @default.
• W4385348531 hasConcept C515207424 @default.
• W4385348531 hasConcept C55493867 @default.
• W4385348531 hasConcept C71924100 @default.
• W4385348531 hasConcept C90924648 @default.
• W4385348531 hasConceptScore W4385348531C126322002 @default.
• W4385348531 hasConceptScore W4385348531C134018914 @default.
• W4385348531 hasConceptScore W4385348531C185592680 @default.
• W4385348531 hasConceptScore W4385348531C2776580952 @default.
• W4385348531 hasConceptScore W4385348531C2777305461 @default.
• W4385348531 hasConceptScore W4385348531C2777573094 @default.
• W4385348531 hasConceptScore W4385348531C2778213512 @default.
• W4385348531 hasConceptScore W4385348531C515207424 @default.
• W4385348531 hasConceptScore W4385348531C55493867 @default.
• W4385348531 hasConceptScore W4385348531C71924100 @default.
• W4385348531 hasConceptScore W4385348531C90924648 @default.
• W4385348531 hasIssue "3" @default.
• W4385348531 hasLocation W43853485311 @default.
• W4385348531 hasOpenAccess W4385348531 @default.
• W4385348531 hasPrimaryLocation W43853485311 @default.
• W4385348531 hasRelatedWork W139093599 @default.
• W4385348531 hasRelatedWork W1817506345 @default.
• W4385348531 hasRelatedWork W1907722009 @default.
• W4385348531 hasRelatedWork W1993344466 @default.
• W4385348531 hasRelatedWork W2049771744 @default.
• W4385348531 hasRelatedWork W2076304007 @default.
• W4385348531 hasRelatedWork W2109001935 @default.

• next